Sen. Elizabeth Warren (D-Mass.) called out President Donald Trump on Wednesday over his claims that TrumpRx is lowering drug costs by 600%, saying the math simply does not add up.
‘As Empty As This Glass’
Warren posted a video on X using a glass of water to illustrate her point. She filled the glass to the brim, called it 100% full, then poured it out entirely — leaving nothing behind.
“Unfortunately, Trump’s promise to lower costs is as empty as this glass,” Warren said, arguing that reducing something by more than 100% is mathematically impossible.
The White House did not immediately respond to Benzinga’s request for comment.
What TrumpRx Actually Is
Trump launched TrumpRx.gov in February alongside Dr. Mehmet Oz and Airbnb co-founder Joe Gebbia, saying people will “save a lot of money and be healthy.” The platform does not sell medicines directly. It lets consumers search for discounted drug prices and print coupons to use at pharmacies or manufacturers’ websites.
At launch, 40 medicines from five companies — AstraZeneca PLC (NYSE:AZN), Eli Lilly And Co. (NYSE:LLY), EMD Serono, a unit of Merck KGaA (OTC:MKGAF) (OTC:MKKGY), Novo Nordisk (NYSE:NVO), and Pfizer Inc. (NYSE:PFE) were listed under most-favored-nation pricing deals with the Trump administration.
The platform has since expanded. Amgen Inc. (NASDAQ:AMGN) and GSK plc (NYSE:GSK) joined TrumpRx in March, bringing the total to 54 discounted drugs. Amgen listed Amjevita at $299, down from $1,484 an 80% discount.
Mixed Reviews
The platform has drawn divided opinion. Billionaire entrepreneur Mark Cuban praised TrumpRx in March, saying it was “saving patients money on IVF and a few other drugs. A lot of money.” Cuban urged critics to give it time.
However, Novartis AG (NYSE:NVS) CEO Vas Narasimhan flagged risks from MFN pricing just this week, calling it a “very difficult situation” and warning that long-term implications for drugmakers and patient access could be significant.
Stephen Ubl, CEO of PhRMA, also cautioned that government-imposed MFN policies risk slowing drug innovation and increasing reliance on China.
Disclaimer: This content was produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock
Login to comment